IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

Journal: Nature Medicine

Published: 2020-06-01

DOI: 10.1038/s41591-020-0911-7

Affiliations: 4

Authors: 22

Go to article
Institutions Share
Spark Therapeutics, Inc., United States of America (USA) 0.48
Integrated Genetic Approaches in Therapeutic Discovery for Rare Diseases (INTEGRARE), France 0.39
Cordelier Research Center (CRC), France 0.14